What is Haemonetics Corp worth?
With the base-case assumptions below, a discounted cash flow model on Haemonetics Corp's reported free cash flow gives $107.87 per share. The share price was $105.30 on September 25, 2026, 2% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 4.0% | 10.0% | $58.20 | -45% |
| Base | 9.0% | 9.0% | $107.87 | +2% |
| Bull | 14.0% | 8.0% | $200.53 | +90% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $144.28 | $155.48 | $169.16 | $186.27 | $208.27 |
| 8.0% | $117.04 | $124.31 | $132.89 | $143.19 | $155.78 |
| 9.0% | $97.17 | $102.14 | $107.87 | $114.55 | $122.45 |
| 10.0% | $82.06 | $85.59 | $89.59 | $94.17 | $99.45 |
| 11.0% | $70.20 | $72.79 | $75.68 | $78.94 | $82.63 |
Where the presets come from
Base: years 1 to 5 grow at Haemonetics Corp's revenue growth rate over the last 5 fiscal years (8.9% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions